Stocks making the biggest moves midday: Eli Lilly, Hasbro, Philip Morris, Intel, Micron & more

FDA approved Foundayo, Eli Lilly's once‑a‑day GLP‑1 obesity pill, and Lilly shares rose ~4%. Intel will repurchase a 49% stake in its Ireland Fab 34 JV from Apollo for $14.2B (funded with cash and roughly $6.5B new debt), sending its stock up ~9% and supporting strength in semiconductors and memory names (SanDisk +10%, Western Digital +11%, Micron +10%). Company results and guidance drove large swings: Dave & Buster's jumped ~20% on stronger 2026 outlook, PVH and Cal‑Maine beat estimates, NCino topped revenue guide, while RH plunged ~23% and Nike fell ~14% after a slight North America miss and analyst downgrades. Hasbro disclosed a cybersecurity incident and Philip Morris slid >5% after Reuters reported the FDA delayed authorization for nicotine pouches; oil names fell as WTI traded below $100, while Newmont jumped ~6% on higher gold.

Analysis

Market moves today read as a short-duration rotation: reopening of beaten-down cyclicals (memory, parts of semi cap) and rapid sentiment-driven re-pricing of consumer and single-event risk names. Inventory dynamics in memory tend to swing sharply; if cloud/data-center restocking continues, an outsized 20–40% revisit in earnings power for mid-cap flash/HDD names is realistic over 3–9 months, but the cycle can reverse just as fast on a single large OEM order cancellation.

Strategic capital redeployment by large chip manufacturers that increases direct control over advanced-node capacity materially shifts bargaining power upstream to the IDM — expect tighter wafer allocation for pure-play foundries, 200–400bps of gross-margin tailwinds to the owner over 2–3 years, and nearer-term balance-sheet strain as buy-ins are often funded with a mix of cash and new debt that compresses flexibility for M&A or dividends for 12–24 months.

On the consumer side, bifurcation is being amplified: brands that can translate margin improvement into execution beats will attract flows, while those with perception or execution misses draw rapid analyst downgrades and outsized share declines. Separately, idiosyncratic operational shocks (cybersecurity, regulation, product scrutiny) are now trading more like 30–60 day liquidity events that require monitoring of insurance recoveries, incremental CapEx, and re-contracting costs (supply chain and distribution) rather than pure demand narratives.

Key macro/sector catalysts to watch are: direction of oil on geopolitical headlines (days–weeks), wholesale memory inventory reads from hyperscalers (1–3 months), and any regulatory pronouncements impacting nicotine/consumer-health alternatives (months). Each of those can flip current sentiment quickly; position sizing should reflect binary outcomes and high intraday vol.

Key Decisions for Investors

• Long INTC (12-month horizon): buy and hold for 12 months expecting 25–35% upside if advanced-node control drives 200–400bps margin expansion; tactically sell 1–2 quarter calls to finance position. Risk: balance-sheet leverage or weaker-than-expected process yields; hard stop at -12% from entry.
• Pair trade — Long PVH / Short NKE (3–6 months): overweight PVH for brand/margin resilience and short NKE to hedge consumer discretionary rotation risk. Target relative outperformance of 15% in 3–6 months; size so P&L neutral to broader market moves. Cut pair if NKE rallies >8% on confirming demand signals.
• Memory basket via defined-risk options (SNDK, WDC, STX; 3-month horizon): buy 3-month call spreads (buy ATM, sell 20–25% OTM) to capture continuation of restocking; expect 30–50% return on premium if recovery sustains. Risk: abrupt destocking; limit total premium exposure to <=2% of equity book.
• Trade energy tail-risk (6–12 weeks): buy 1–3 month puts on CVX and XOM or long an inverse energy ETF if Brent fails to reassert >$105 — target 8–15% downside in equities. Hedge: unwind if geopolitical upside drives Brent >$110 or if inventory data signals tightening.
• Short HAS via near-dated puts (30–60 days): buy puts to express downside from operational/brand remediation costs and potential insurance lag; target 15–25% downside. Risk: swift containment and minimal financial impact; cap allocation to single-digit percent of book and tighten if remediation disclosures are unequivocally positive.